China NMPA Drug Inspection - Shaanxi Xiyue Pharmaceutical Co., Ltd. - Hydrochlorothiazide tablets
China NMPA drug inspection for Shaanxi Xiyue Pharmaceutical Co., Ltd. published February 06, 2018. Drug: Hydrochlorothiazide tablets. The Guangxi Zhuang Autonomous Region Food and Drug Administration (GXFDA) issued its First Drug Quality Announcement of
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Shaanxi Xiyue Pharmaceutical Co., Ltd. published February 06, 2018. Drug: Hydrochlorothiazide tablets. The Guangxi Zhuang Autonomous Region Food and Drug Administration (GXFDA) issued its First Drug Quality Announcement of
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox